Related Experiment Video
Updated: Mar 12, 2026
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
18.1K
[Rivaroxaban as monotherapy in patients with venous thromboembolism]
E P Krivoshchekov1, I A Migunov1, V E Romanov1
1V.D. Seredavin Samara Regional Clinical Hospital, Samara State Medical University, Ministry of Health of the Russian Federation, Samara, Russia.
Khirurgiia
|November 3, 2016
Summary
Rivaroxaban demonstrates a favorable benefit profile for treating venous thromboembolism (VTE). This study suggests rivaroxaban can be considered for initial VTE therapy, showing comparable efficacy and safety to traditional treatments.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Venous thromboembolism (VTE) represents a significant cause of mortality and a major health concern.
- Anticoagulants are the primary treatment for VTE.
- Rivaroxaban, a novel anticoagulant, was the first approved for VTE treatment and secondary prevention in Russia.
Purpose of the Study:
- To evaluate the efficacy and safety of rivaroxaban for VTE treatment initiated on the first day.
- To compare rivaroxaban's outcomes against traditional anticoagulant therapy.
Main Methods:
- A comparative study involving 78 patients in the control group (LMWH and VKA) and 46 patients in the rivaroxaban group.
- Treatment duration was a minimum of 3 months.
- Outcomes assessed included thrombus deterioration and bleeding complications.
Main Results:
- Thrombus deterioration occurred in 3.85% of the control group versus 2.2% in the rivaroxaban group.
- Bleeding complications were observed in 7.7% of the LMWH/VKA group compared to 4.3% in the rivaroxaban group.
Conclusions:
- Rivaroxaban exhibits a favorable benefit profile in patients with VTE.
- Rivaroxaban can be considered as an initial therapeutic option for VTE management.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
445
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
445
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:30Venous Thrombosis IV: Nursing Management
352
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
352
01:30Venous Thrombosis I: Introduction
618
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
618
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
418
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
418
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K